Zevra Therapeutics (ZVRA) Interest Expenses (2014 - 2026)

Zevra Therapeutics (ZVRA) has 13 years of Interest Expenses data on file, last reported at $1.7 million in Q1 2026.

• Quarterly Interest Expenses fell 70.65% year-over-year to $1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.9 million (down 16.31% YoY) and the FY2025 annual result came in at $91.5 million, down 37.48% from the prior year.
• Interest Expenses rose to $1.7 million in Q1 2026, from -$892000.0 in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $6.5 million in Q3 2024 to a low of -$892000.0 in Q4 2025.
• A 5-year average of $2.0 million and a median of $1.7 million in 2026 frame the typical range for Interest Expenses.
• Annual changes were most pronounced in 2023 — Interest Expenses surged 26440.0% — and 2025, when it tumbled 140.66%.
• Tracing ZVRA's Interest Expenses over 5 years: stood at $170000.0 in 2022, then jumped by 514.71% to $1.0 million in 2023, then soared by 109.95% to $2.2 million in 2024, then slumped by 140.66% to -$892000.0 in 2025, then jumped by 291.82% to $1.7 million in 2026.
• The last three Interest Expenses figures came in at $1.7 million (Q1 2026), -$892000.0 (Q4 2025), and $2.1 million (Q3 2025), per Business Quant data.